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 Abstract: 
 
Objective: Treatment of mood and behavioral symptoms in geriatric patients with advanced 
dementia may be impeded by poor compliance with oral medications.   Pluronic lecithin 
organogel (PLO) is a compounding substrate that can be used for the topical administration of 
psychotropic medications.   
 
 
Methods: Charts of patients treated with psychotropic medications compounded with PLO 
cream were reviewed for treatment outcomes.  All patients were treated by a nursing home 
outreach service. 
 
 
Results: Records from twenty-four patients, mean age 86.8 + 5.9, were reviewed.  Common 
psychiatric symptoms included agitation, aggressive behavior, and depression.  Medications 
most commonly administered as a PLO cream included quetiapine and venlafaxine.  All patients 
had mild to marked improvement in psychiatric symptoms.  
 
 
Conclusions: Pluronic lecithin organogel (PLO) may be an effective option for the topical 
administration of psychiatric medications in geriatric patients with dementia who are not 
compliant with oral medications.  
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 Introduction: 
 
More than eighty percent of geriatric patients with dementia develop mood and behavioral 
symptoms during the course of their illness.1,2  Psychotropic medications can effectively treat 
these symptoms.  However, patients with dementia may not comply with oral medications due to 
behavioral issues, paranoia or swallowing difficulty.  Alternative routes for administering 
medications are needed to increase compliance and improve outcomes.   
 
During the past 20 years, several drugs have been formulated for topical administration including 
scopolamine, nitroglycerin, nicotine, rivastigmine and fentanyl.  These drugs are combined with 
permeation enhancers to increase passive transdermal diffusion through the skin into the 
circulation.  Currently, selegiline and methylphenidate are the only psychotropic medications 
available in a transdermal formulation. 
 
Pluronic lecithin organogel (PLO) is a synthetic compound developed in the 1990s as a 
transdermal drug delivery substrate.3,4,5  When combined with a therapeutic agent, PLO forms 
drug micelles in a thermodynamically stable cream.  The FDA permits the mixing and physical 
modification (compounding) of medications by a pharmacist upon receipt of a prescription from 
a licensed practitioner to meet the unique needs of an individually identified patient.  
Compounding psychotropic medications with PLO can offer new treatment options for geriatric 
patients with dementia.  
 
PLO has three major components; lecithin, isopropyl palmitate, and poloxamer (Pluronic).  All 
three components act as skin permeation enhancers.  Lecithin is a naturally occurring fatty 
substance which is a surfactant and acts as an emulsifier.  Isopropyl palmitate is a palm oil based 
moisturizer and thickening agent.  Both lecithin and isopropyl palmitate are commonly used in 
various topical products and can effectively dissolve lipophilic drugs.  Poloxamer is a copolymer 
of polyoxypropylene and polyoxyethylene, and is FDA approved for human use.  The structure 
of poloxamer promotes the formation of drug micelles when mixed with lecithin and isopropyl 
palmitate.  A thermodynamically stable cream is formed when the three components are mixed 
together.    
 
At this time, there are very few studies evaluating the clinical effectiveness of medications 
applied topically using PLO.  Two recent prospective trials reported improvement in nausea and 
vomiting induced by chemotherapy when patients were treated with lorazepam, 
diphenhydramine and haloperidol compounded with PLO.6,7 These trials concluded that 
administering medications topically via PLO reduces gastrointestional side effects and improves 
patient compliance, without significant skin irritation.  However, in a study evaluating the 
plasma concentrations of lorazepam (2mg), diphenhydramine (25mg) and haloperidol (2mg) 
administered topically using PLO; lorazepam and haloperidol were not detectable, and only five 
of the 10 subjects had detectable plasma levels of diphenhydramine.8   
 
To our knowledge, there are no studies assessing the effectiveness of topically applied 
psychotropic medications compounded with PLO cream for the treatment of psychiatric 
symptoms.  For a number of years, we have used PLO creams to administer psychiatric 
medications in elderly patients who are unable or unwilling to take oral medications.  For this 
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 study, we reviewed the records of 24 geriatric patients who were treated with psychiatric 
medications applied topically using PLO cream.  All patients had advanced dementia with 
psychiatric symptoms that significantly impacted the patient’s quality of life or caretakers’ 
ability to provide basic care, and were unwilling or unable to take oral medications.   
 
Methods:  
 
A retrospective chart review was carried out by the authors on all geriatric psychiatry patients 
treated with topical psychotropic medications using PLO.  A structured data collection form was 
used to collect data including age, gender, living situation, medications, medical and psychiatric 
diagnoses, psychiatric/behavioral symptoms and the Mini Mental State Exam score (MMSE).9  
The authors accessed response to therapy by reviewing the medical record, which contained the 
nursing staff and physician’s clinical assessment of patients.  Response was rated on a 4 point 
scale; (1) no improvement, (2) mild improvement, (3) moderate improvement, or (4) marked 
improvement.  Statistical analysis was carried out using SPSS for descriptive variables.   
 
Results:  
 
Twenty-four geriatric psychiatry records were reviewed.  Demographic and clinical variables are 
shown in Table 1.  All patients had severe dementia and resided in skilled nursing facilities.  
Psychiatric diagnoses included major depression (n = 17, 70.8%) and mood disorder secondary 
to general medical condition (n = 3, 12.5%).  Medical conditions included hypertension (n = 17, 
70.8%), stroke (n = 12, 50%), coronary artery disease (n = 8, 33.3%), hyperlipidemia (n = 6, 
25%), diabetes (n = 2, 8.3%), hypothyroidism (n = 5, 20.8%), seizure disorder (n = 3, 12.5%) 
and osteoarthritis (n = 5, 20.8%).   
  
95
Marshall Journal of Medicine, Vol. 1 [2015], Iss. 1, Art. 4
https://mds.marshall.edu/mjm/vol1/iss1/4
DOI: http://dx.doi.org/10.18590/mjm.2015.vol1.iss1.4
 Table 1.  Demographics, Clinical Characteristics and Outcomes    
Demographics 
    Age, years [mean (SD)]       86.8 (5.9) 
    Female      20 (83.3%) 
    Male          4 (16.7%) 
Type of dementia       
    Alzheimer’s         12 (50%) 
    Vascular         7 (29.2%) 
    Alzheimer’s and Vascular       5 (20.8%) 
MMSE, previous 6 months, 9 pts [mean (SD)] 2.7 (5.7) 
MMSE, previous 2 years, 15 pts [mean (SD)] 12.8 (8.6) 
Psychiatric symptoms     
    Depressed mood [number (%)]   15 (62.6%)   
    Aggression and agitation    19 (79.2%) 
    Decreased appetite     10 (41.7%) 
    Insomnia         5 (20.8%) 
    Wandering         3 (12.5%) 
    Psychosis            2 (8.3%) 
    Anxiety           2 (8.3%) 
Outcome      
    No improvement            0 (0%) 
    Minimal improvement      4 (16.7%) 
    Moderate improvement     14 (58.3%) 
    Marked improvement          6 (25%) 
 
 
Reasons for starting PLO psychiatric medications included: physical aggressiveness and 
agitation (n = 19, 79.2%), depressive symptoms (n = 15, 62.5%), decreased appetite (n = 10, 
41.7%), insomnia (n = 5, 20.8%), and psychotic symptoms (n = 2, 8.3%).  Six different 
psychiatric medications were used in PLO formulation: quetiapine, venlafaxine, trazodone, 
buspirone, escitalopram and lorazepam.  
 
Quetiapine was used in eighteen patients at an individual dosage range from 12.5 mg to 100 mg 
(mean = 57.6 ± 34.9), given one to four times a day, for a total daily dose of 25 mg to 300 mg 
(mean = 136.1 ± 97.5).  Mean duration of treatment was 5.3 ± 4.6 months.  
 
Venlafaxine was used in fifteen patients at an individual dose range of 37.5 mg to 100 mg (mean 
= 66.6 ± 17.6).  Venlafaxine was administered twice a day in fourteen patients and three times a 
day in one patient.  Total daily dose of venlafaxine ranged between 75 mg to 200 mg (mean= 
135.7 ± 37.9), and mean duration of treatment was 5.5 ± 4.4 months at time of review.  Nine 
patients were treated with both quetiapine PLO cream and venlafaxine PLO cream.   
 
Five patients received trazodone PLO cream at a dose of 50 mg to 100 mg at bedtime for 
insomnia (mean= 70 ± 27.4).  The mean duration of treatment with trazodone was 3 + 1.4 
months at time of chart review.  Four patients who were treated with topical trazodone also 
received topical quetiapine and two received topical venlafaxine.  Two patients received topical 
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 buspirone at a dose of 5-10 mg (mean = 7.5 ± 3.5).  Buspirone was administered three times a 
day with a total daily dose between 15-30 mg (mean= 22.5 ± 10.6).  One hospice patient received 
1mg lorazepam PLO cream four times a day.  One patient received 20mg escitalopram PLO 
cream daily for 11 months.   
 
Before starting PLO medication, all patients had been non-compliant with or unable to take oral 
medications.  PLO compounded medications were applied to the inner aspect of the forearm in 
all patients except one who had PLO cream applied to his back due to physical aggressiveness.  
No side effects were reported in any of the patients.   
 
All patients benefited from PLO medications as shown in Table 1.  Improvement in symptoms 
were as follows: 12 patients (50%) were more compliant with oral medications, 13 of 19 (68.4%) 
patients with severe agitation improved, 11 of 15 (73.3%) patients with depressive mood 
improved, 6 of 10 (60%) patients had improved appetite, and 2 of 5 (40%) had improvement in 
sleep.   Two patients who received PLO for psychotic symptoms were rated as moderately 
improved. 
 
The following two clinical vignettes illustrate the use of psychotropic PLO cream. 
 
 
Case Vignettes 
 
Subject 1 
Ms. A was a 78 year-old woman with vascular dementia, who was referred for evaluation of 
depression, behavioral disturbance and poor appetite.  Ms. A stated that her mood was “not too 
good”, and she was irritable, anxious and uncooperative with care by nursing home staff.  Mini-
Mental State Examination  was 7/30.  She was treated with oral venlafaxine extended-release 
75mg daily with improvement of appetite and mood, however she continued to be anxious and 
was uncooperative.  Buspirone 5mg bid was used with good results.  Over the following year, 
her cognitive impairment progressed and she became uncooperative with all oral medication.  
Her depressive and behavioral symptoms returned.  She was started on venlafaxine 50mg PLO 
topical cream bid and buspirone 10mg PLO topical cream bid.  Four weeks after starting PLO 
cream, the nursing home staff reported significant improvement in her depressive and behavioral 
symptoms.   
 
Subject 2  
Mr. B was an 84 year-old man diagnosed with mixed type (Alzheimer’s and Vascular) dementia, 
who was referred for evaluation of insomnia and severe aggression toward staff and other 
residents.  MMSE was 0/30.  Eventually, the patient was treated with a medication regimen of 
quetiapine 100mg bid, valaproic acid syrup 750mg bid and trazodone 50mg qhs, with marked 
improvement in his behavior. However after 2 years, he became uncooperative with oral 
medications and experienced recurrence of aggression.  Strategies to improve compliance were 
unsuccessful and oral medications were discontinued.  PLO quetiapine cream 100mg bid and 
trazodone 50mg PLO cream qpm were begun.  He was compliant with PLO medications and 
within two months his behavior markedly improved.   
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 Discussion:  
 
Patients with advanced dementia frequently do not comply with oral medications due to 
behavioral issues, paranoid thoughts about treatment intentions, or difficulty with swallowing 
pills.  Transdermal administration of medications in this patient population offer many 
advantages including improved tolerability, ease of administration, and steady continuous 
delivery rate.  Pluronic lecithin organogel (PLO) is a synthetic compound that has been 
developed as a substrate for the topical administration of therapeutic agents.  
 
A limited number of studies have evaluated the bioavailability of medications administered 
topically when combined with PLO cream.  Finding from these studies typically reveal low or 
undetectable serum levels of medications, however, the doses of medications used in these 
studies may be too low for adequate transdermal absorption.10,11  For example, Glisson et al. 
administered promethazine 50mg compounded with PLO in 15 subjects; blood samples were 
collected over a 6 hour period.12  Only 65% of the blood samples had measurable serum 
concentrations of promethazine, and only 39.2% of these samples contained quantifiable 
concentrations of the drug equal to or greater than 1 ng/mL.  Interestingly, eleven of the fifteen 
subjects in this study experienced drowsiness.  In another study, methadone (dose range 10mg to 
45mg) compounded with PLO was administered topically to ten subjects.13  Only one subject 
who received the 45mg dose of methadone achieved measurable serum levels.  These studies 
suggest that when compounding a medication with PLO for topical application, a higher dose of 
medication is needed in order to obtain serum levels similar to that observed with oral 
administration.  The reduced absorption of medications when administered transdermally is 
reflected by the fact that currently available transdermal therapeutic patches are formulated with 
significantly higher doses of the therapeutic agent when compared to oral formulations.  For 
example, methylphenidate patch contain between 27.5mg to 82.5mg per patch, selegiline patch 
contain between 20mg to 40mg per patch, and rivastigmine patch contains 9mg to 27mg per 
patch.   
 
In our case series, a variety of psychotropic medications were administered topically using PLO 
cream in patients unwilling or unable to take oral medications.  Based on our retrospective chart 
reviews, all patients demonstrated some clinical improvement in their psychiatric symptoms.  
This case series was limited to geriatric patients with dementia; however other groups of patients 
with psychiatric disorders may benefit from PLO compounded medications.   
 
Our study has a number of limitations, including the retrospective observational design and small 
sample size.  Because of the observational design, we cannot rule out the possibility that the 
observed improvements were due to placebo effect of PLO cream application.  Also, we assessed 
the effectiveness of several different psychotropic medications applied topically with PLO 
cream, which limits the conclusions that can be draw concerning the effectiveness of any specific 
agent.  However, the goal of this study was to demonstrate that compounding medications with 
PLO for topical application may offer an effective alternative for treatment of complex geriatric 
patients.  There may be concerns about the patient population in this study; however clinical 
trials have not consistently revealed any significant differences in transdermal absorption of 
medications when comparing young and old patients.14  
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 In conclusion, compounding psychotropic medications with pluronic lecithin organogel (PLO) 
provides the opportunity for topical application of a wide range of medications.  However, more 
research is needed to determine the absorption rates and bioavailability of different medications 
when administered with PLO cream.  Although our series was limited to the use of six 
medications, we expect that other psychiatric medications could be effectively administered as a 
PLO creams, thereby expanding the treatment options for geriatric patients, as well as psychiatric 
patients in general. 
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